Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

Leukemia Research

Volumn 37, Issue 10, 2013, Pages 1271-1277

  Cinar, Munevver ^a   Hamedani, FaridSaei ^a   Mo, Zhicheng ^a   Cinar, Bekir ^a,b   Amin, Hesham M ^c   Alkan, Serhan ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR signaling pathway; Bruton tyrosine kinase (BTK); Ibrutinib; Mantle cell lymphoma

Indexed keywords

B LYMPHOCYTE ANTIGEN; BRUTON TYROSINE KINASE; IBRUTINIB; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CARCINOGENESIS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MANTLE CELL LYMPHOMA; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BCR SIGNALING PATHWAY; BRUTON TYROSINE KINASE (BTK); IBRUTINIB; MANTLE CELL LYMPHOMA;

APOPTOSIS; CELL LINE; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, MANTLE-CELL; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIMIDINES;

EID: 84883556703     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.028     Document Type: Article

References (31)

1. Vose J.M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2012, 87(June (6)):604-609.
2. Nakamura S., Yatabe Y., Seto M. Cyclin D1 overexpression in malignant lymphomas. Pathol Int 1997, 47(July (7)):421-429.
3. Perez-Galan P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2010, 117(January (1)):26-38.
4. Jares P., Colomer D., Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007, 7(October (10)):750-762.
5. Shah B.D., Martin P., Sotomayor E.M. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control 2012, 19(July (3)):227-235.
6. Alinari L., Christian B., Baiocchi R.A. Novel targeted therapies for mantle cell lymphoma. Oncotarget 2012, 3(February (2)):203-211.
7. Witzens-Harig M., Hess G., Atta J., Zaiss M., Lenz G., Scholz C., et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol 2012, 91(November (11)):1765-1772.
8. Weniger M.A., Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol 2011, 48(July (3)):214-226.
9. Buggy J.J., Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012, 31(April (2)):119-132.
10. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(January (7277)):88-92.
11. Advani R.H., Buggy J.J., Sharman J.P., Smith S.M., Boyd T.E., Grant B., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(January (1)):88-94.
12. de Rooij M.F., Kuil A., Geest C.R., Eldering E., Chang B.Y., Buggy J.J., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119(March (11)):2590-2594.
13. Satterthwaite A.B., Witte O.N. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000, 175(June):120-127.
14. Herman S.E., Gordon A.L., Hertlein E., Ramanunni A., Zhang X., Jaglowski S., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(June (23)):6287-6296.
15. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia 2012, 88-96.
16. Honigberg L.A., Smith A.M., Sirisawad M., Verner E., Loury D., Chang B., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010, 107(July (29)):13075-13080.
17. Amin H.M., McDonnell T.J., Medeiros L.J., Rassidakis G.Z., Leventaki V., O'Connor S.L., et al. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003, 127(April (4)):424-431.
18. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006, 1(3):1458-1461.
19. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9(January (1)):47-59.
20. Navarro A., Royo C., Hernandez L., Jares P., Campo E. Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. Semin Hematol 2011, 48(July (3)):155-165.
21. Ek S., Dictor M., Jerkeman M., Jirstrom K., Borrebaeck C.A. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008, 111(January (2)):800-805.
22. Gururajan M., Jennings C.D., Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006, 176(May (10)):5715-5719.
23. Navarro A., Clot G., Royo C., Jares P., Hadzidimitriou A., Agathangelidis A., et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012, 72(October (20)):5307-5316.
24. Ponader S., Chen S.S., Buggy J.J., Balakrishnan K., Gandhi V., Wierda W.G., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2011, 119(February (5)):1182-1189.
25. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120(August (6)):1175-1184.
26. Mohamed A.J., Yu L., Backesjo C.M., Vargas L., Faryal R., Aints A., et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009, 228(March (1)):58-73.
27. Desiderio S. Role of Btk in B cell development and signaling. Curr Opin Immunol 1997, 9(August (4)):534-540.
28. Park H., Wahl M.I., Afar D.E., Turck C.W., Rawlings D.J., Tam C., et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 1996, 4(May (5)):515-525.
29. Brown J.R. Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials. Curr Hematol Malig Rep 2013, 8(March (1)):1-6.
30. Dasmahapatra G., Patel H., Dent P., Fisher R.I., Friedberg J., Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013, 161(April (1)):43-56.
31. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, (June). [published online ahead of print June 19 2013]. N Eng J Med 2013. http://www.nejm.org/doi/full/10.1056/NEJMoa1306220#t=article.